93 related articles for article (PubMed ID: 1270806)
1. Receptors for immune complexes on cells within a non-lymphoid murine tumor.
Braslawsky GR; Yaackubowicz M; Frensdorff A; Witz IP
J Immunol; 1976 Jun; 116(6):1571-8. PubMed ID: 1270806
[TBL] [Abstract][Full Text] [Related]
2. Receptors for immune complexes on cells within a polyoma virus-induced murine sarcoma.
Braslawsky GR; Serban D; Witz IP
Eur J Immunol; 1976 Aug; 6(8):579-83. PubMed ID: 185060
[TBL] [Abstract][Full Text] [Related]
3. Receptor sites for antigen-antibody complexes on cells derived from solid tumors: detection by means of antibody sensitized sheep erythrocytes labeled with technetium-99m.
Wood GW; Gillespie GY; Barth RF
J Immunol; 1975 Mar; 114(3):950-7. PubMed ID: 1089728
[TBL] [Abstract][Full Text] [Related]
4. Follicular dendritic cells in suspension: identification, enrichment, and initial characterization indicating immune complex trapping and lack of adherence and phagocytic activity.
Schnizlein CT; Kosco MH; Szakal AK; Tew JG
J Immunol; 1985 Mar; 134(3):1360-8. PubMed ID: 3968423
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
6. Xenoantisera against a murine T cell tumor product cross-react with immunoglobulin Fab determinants.
Mackel AM; Craddock GR; Warr GW; DeLuca D; Marchalonis JJ
J Immunol; 1983 Sep; 131(3):1582-90. PubMed ID: 6350458
[TBL] [Abstract][Full Text] [Related]
7. Virus-induced immune complex disease: genetic control of C1q binding complexes in the circulation of mice persistently infected with lymphocytic choriomeningitis virus.
Oldstone MB; Tishon A; Buchmeier MJ
J Immunol; 1983 Feb; 130(2):912-8. PubMed ID: 6217255
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
9. In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens.
Kruisbeek AM; Titus JA; Stephany DA; Gause BL; Longo DL
J Immunol; 1985 Jun; 134(6):3605-14. PubMed ID: 2580891
[TBL] [Abstract][Full Text] [Related]
10. Characterization of antigen-binding receptors in vitro. I. An equilibrium method for measuring antigen binding in murine cells.
Benfari MJ; Cooperband SR; Moolten FL
J Immunol; 1977 Oct; 119(4):1427-31. PubMed ID: 894047
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of Fc receptor expression in guinea pig peritoneal exudate macrophages by muramyl dipeptide or lipopolysaccharide.
Yagawa K; Kaku M; Ichinose Y; Nagao S; Tanaka A; Aida Y; Tomoda A
J Immunol; 1985 Jun; 134(6):3705-11. PubMed ID: 2985692
[TBL] [Abstract][Full Text] [Related]
12. Soluble factors produced during an immune response regulate Ia antigen expression by murine adenocarcinoma and fibrosarcoma cells.
Callahan GN
J Immunol; 1984 May; 132(5):2649-57. PubMed ID: 6201554
[TBL] [Abstract][Full Text] [Related]
13. Activation of murine T cells by toxic shock syndrome toxin-1. The toxin-binding structures expressed on murine accessory cells are MHC class II molecules.
Uchiyama T; Tadakuma T; Imanishi K; Araake M; Saito S; Yan XJ; Fujikawa H; Igarashi H; Yamaura N
J Immunol; 1989 Nov; 143(10):3175-82. PubMed ID: 2509554
[TBL] [Abstract][Full Text] [Related]
14. In vivo treatment with anti-I-A antibodies: differential effects on Ia antigens and antigen-presenting cell function of spleen cells and epidermal Langerhans cells.
Aberer W; Kruisbeek AM; Shimada S; Katz SI
J Immunol; 1986 Feb; 136(3):830-6. PubMed ID: 3455705
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors.
Baiu DC; Prechl J; Tchorbanov A; Molina HD; Erdei A; Sulica A; Capel PJ; Hazenbos WL
J Immunol; 1999 Mar; 162(6):3125-30. PubMed ID: 10092761
[TBL] [Abstract][Full Text] [Related]
16. Penetration and binding of antibodies in experimental human solid tumors grown in mice.
Ong GL; Mattes MJ
Cancer Res; 1989 Aug; 49(15):4264-73. PubMed ID: 2743313
[TBL] [Abstract][Full Text] [Related]
17. Specific inhibition of hybrid resistance in F1 hybrid mice pretreated with parent-strain spleen cells. II. Evidence for an Hh-1 antigen-specific tolerization.
Kosmatopoulos K; Scott-Algara D; Halle-Pannenko O
J Immunol; 1988 Nov; 141(10):3285-92. PubMed ID: 2460528
[TBL] [Abstract][Full Text] [Related]
18. Production of BSF-1 during an in vivo, T-dependent immune response.
Finkelman FD; Ohara J; Goroff DK; Smith J; Villacreses N; Mond JJ; Paul WE
J Immunol; 1986 Nov; 137(9):2878-85. PubMed ID: 3489779
[TBL] [Abstract][Full Text] [Related]
19. Multiple splenic lymphoid cell subpopulations regulate H-2 antigen expression on teratocarcinoma cells in vivo.
Ostrand-Rosenberg S; Cohn AL; Sandoz JW
J Immunol; 1983 Jun; 130(6):2969-73. PubMed ID: 6133895
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
